These findings imply that olaparib could be a more effective treatment option for individuals with HER2-negative metastatic BC who have a germline BRCA mutation [2, 11]. In the EMBRACA trial, 431 patients were randomized, 287 receiving talazoparib and 144 standard therapy. The gene discussed is ERBB2; the disease is breast cancer.